专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

61. 发明授权

US09593163B2 Oncostatin M receptor antigen binding proteins 有权
标题翻译：制瘤素M受体抗原结合蛋白
公开(公告)号：US09593163B2
公开(公告)日：2017-03-14
申请号：US15279305
申请日：2016-09-28
申请人： Kiniksa Pharmaceuticals, Ltd.
发明人： Heather A. Arnett , Sabine S. Escobar , Chadwick T. King , Ai Ching Lim , Saravanakumar Narayanan , Paul H. Weinreb , Nels E. Pederson
IPC分类号： C07K16/24 , C07K16/28 , A61K39/395
CPC分类号： C07K16/2866 , A61K39/395 , C07K16/244 , C07K16/248 , C07K16/28 , C07K2317/21 , C07K2317/515 , C07K2317/56 , C07K2317/565 , C07K2317/76 , C07K2317/92
摘要： The invention provides anti-oncostatin M receptor-β (OSMR) antigen binding proteins, e.g., antibodies and functional fragments, derivatives, muteins, and variants thereof. OSMR antigen binding proteins interfere with binding of OSM and/or IL-31 to OSMR. In some embodiments, anti-OSMR antigen binding proteins are useful tools in studying diseases and disorders associated with OSMR and are particularly useful in methods of treating diseases and disorders associated with OSMR and binding of OSM and/or IL-31 to OSMR.
摘要翻译：本发明提供抗制酒石素M受体-β（OSMR）抗原结合蛋白，例如抗体和功能片段，衍生物，突变蛋白及其变体。 OSMR抗原结合蛋白干扰OSM和/或IL-31与OSMR的结合。在一些实施方案中，抗OSMR抗原结合蛋白是研究与OSMR相关的疾病和病症的有用工具，并且特别可用于治疗与OSMR和OSM和/或IL-31与OSMR结合的疾病和病症的方法。

62. 发明申请

US20170067108A1 METHODS OF DIAGNOSING AND TREATING EOSINOPHILIC DISORDERS 审中-公开
标题翻译：诊断和治疗嗜酸细胞性疾病的方法
公开(公告)号：US20170067108A1
公开(公告)日：2017-03-09
申请号：US15136677
申请日：2016-04-22
申请人： Genentech, Inc.
发明人： ALEXANDER R. ABBAS , JOSEPH R. ARRON , DAVID F. CHOY , GUIQUAN JIA , NICHOLAS J.I. LEWIN-KOH , KATRINA B. MORSHEAD
IPC分类号： C12Q1/68 , C07K16/24 , C07K16/42
CPC分类号： C12Q1/6883 , A61K2039/545 , A61K2039/55 , C07K16/244 , C07K16/4291 , C07K2317/24 , C07K2317/31 , C12Q2600/106 , C12Q2600/158
摘要： Methods of diagnosing and treating disorders related to excess eosinophil numbers or activity, including but not limited to asthma, are provided. Also provided are methods of selecting or identifying patients for treatment with certain therapeutic agents that are TH2 pathway inhibitors.
摘要翻译：提供诊断和治疗与过量嗜酸性粒细胞数目或活性相关的疾病的方法，包括但不限于哮喘。还提供了选择或鉴定患者以治疗TH2途径抑制剂的某些治疗剂的方法。

63. 发明申请

US20170066824A1 ANTI-INTERLEUKIN ANTIBODY PREPARATIONS FOR DELIVERY INTO A LUMEN OF THE INTESTINAL TRACT USING A SWALLOWABLE DRUG DELIVERY DEVICE 审中-公开
标题翻译：使用易挥发性药物递送装置将抗胰蛋白酶抗体制剂递送入肠内诱导物
公开(公告)号：US20170066824A1
公开(公告)日：2017-03-09
申请号：US15150379
申请日：2016-05-09
申请人： Rani Therapeutics, LLC
发明人： Mir Imran , Radhika Korupolu , Elaine To , Mir Hashim
IPC分类号： C07K16/24 , A61M25/10
CPC分类号： C07K16/244 , A61K38/26 , A61K38/28 , A61M25/10 , A61M2025/105 , C07K16/2866 , C07K2317/24 , C07K2317/76
摘要： Embodiments of the invention provide swallowable devices, preparations and methods for delivering therapeutic agents within the GI tract such as neutralizing proteins (NP) particularly antibodies which neutralize interleukins. Many embodiments provide a swallowable device e.g., a capsule for delivering various agents into the intestinal wall (IW). Embodiments also provide agent preparations that are configured to be contained within the capsule, advanced from the capsule into the IW and degrade to release the agent into the bloodstream to produce a therapeutic effect. The preparation can be operably coupled to delivery means having a first configuration where the preparation is contained in the capsule and a second configuration where the preparation is advanced out of the capsule into the IW. Embodiments of the invention are particularly useful for the delivery of interleukin NP's (INP) for treatment of inflammatory conditions where such INP's are poorly absorbed, tolerated and/or degraded within the GI tract.
摘要翻译：本发明的实施方案提供了用于递送胃肠道内的治疗剂的吞咽装置，制剂和方法，例如中和蛋白质（NP），特别是中和白细胞介素的抗体。许多实施例提供了可吞咽的装置，例如用于将各种药剂输送到肠壁（IW）中的胶囊。实施方案还提供被配置为包含在胶囊内的药剂制剂，其从胶囊进入IW并降解以将药剂释放到血流中以产生治疗效果。制剂可以可操作地偶联至具有第一配置的递送装置，其中制剂被包含在胶囊中，并且第二配置将制剂从胶囊中推出到IW中。本发明的实施方案特别可用于递送用于治疗其中这种INP在胃肠道内不良吸收，耐受和/或降解的炎性病症的白介素NP（INP）。

64. 发明申请

US20170058026A1 METHODS FOR MODULATING IMMUNE RESPONSES DURING CHRONIC IMMUNE CONDITIONS BY TARGETING IL-27 INDUCED PATHWAYS 审中-公开
标题翻译：通过靶向IL-27诱导途径调节慢性免疫条件下免疫应答的方法
公开(公告)号：US20170058026A1
公开(公告)日：2017-03-02
申请号：US15339218
申请日：2016-10-31
申请人： The Brigham and Women's Hospital, Inc.
发明人： Vijay K. Kuchroo , Chen Zhu , Ana Carrizosa Anderson
IPC分类号： C07K16/24 , C12N15/113
CPC分类号： C07K16/244 , A61K31/713 , A61K38/1709 , A61K38/1793 , A61K38/20 , C07K14/47 , C07K14/54 , C07K14/7155 , C07K16/18 , C07K2317/75 , C07K2317/76 , C12N5/0636 , C12N15/1136 , C12N2310/11 , C12N2310/14 , C12N2310/16 , C12N2501/2303 , C12N2501/2327
摘要： Described herein are novel compositions comprising IL-27 or NFIL-3 modulators (i e , inhibitors or activators), and methods using these agents for targeting cells, such as functionally exhausted or unresponsive immune cells, and modulating TIM-3 activity or expression. These compositions, methods, and uses are useful for the treatment of chronic immune conditions, such as persistent infections, cancer, and autoimmune diseases.
摘要翻译：本文描述了包含IL-27或NFIL-3调节剂（即抑制剂或活化剂）的新型组合物，以及使用这些试剂靶向细胞如功能性耗尽或无应答的免疫细胞以及调节TIM-3活性或表达的方法。这些组合物，方法和用途可用于治疗慢性免疫病症，例如持续感染，癌症和自身免疫性疾病。

65. 发明授权

US09580501B2 Anti-TNF alpha monoclonal secretory IgA antibodies and methods for treating inflammatory diseases 有权
标题翻译：抗TNFα单克隆分泌型IgA抗体和治疗炎性疾病的方法
公开(公告)号：US09580501B2
公开(公告)日：2017-02-28
申请号：US14365839
申请日：2012-12-14
申请人： Synthon Biopharmaceuticals B.V.
发明人： Gerardus Joseph Andreas Ariaans , Frans van Dalen , Declan Thomas Nolan
IPC分类号： C07K16/24 , C12N15/82 , A61K9/00 , A61K39/00
CPC分类号： C07K16/241 , A61K9/0053 , A61K39/00 , A61K2039/505 , A61K2039/54 , C07K16/244 , C07K2317/13 , C07K2317/24 , C07K2317/41 , C07K2317/565 , C07K2317/76 , C12N15/8258
摘要： A monoclonal secretory IgA antibody, which binds to and neutralizes human TNFα. The secretory antibody is useful in treating a variety of inflammatory conditions in humans.
摘要翻译：单克隆分泌型IgA抗体，其结合并中和人TNFα。分泌型抗体可用于治疗人类各种炎性疾病。

66. 发明授权

US09555107B2 Compositions and methods for the treatment of diseases and disorders associated with cytokine signaling 有权
标题翻译：用于治疗与细胞因子信号传导相关的疾病和病症的组合物和方法
公开(公告)号：US09555107B2
公开(公告)日：2017-01-31
申请号：US13404241
申请日：2012-02-24
申请人： Yvonne M. Chen , Anan Chuntharapai , Dimitry Danilenko , Wenjun Ouyang , Susan Sa , Patricia Valdez , Terence Wong , Jianfeng Wu , Yan Zheng
发明人： Yvonne M. Chen , Anan Chuntharapai , Dimitry Danilenko , Wenjun Ouyang , Susan Sa , Patricia Valdez , Terence Wong , Jianfeng Wu , Yan Zheng
IPC分类号： A61K39/395 , A61K38/17 , A61K38/20 , C07K16/24 , C07K16/28 , A61K39/00
CPC分类号： A61K39/3955 , A61K38/17 , A61K38/1793 , A61K38/20 , A61K2039/505 , A61K2039/57 , C07K16/244 , C07K16/2866 , C07K2317/76 , C07K2317/92
摘要： Compositions and methods are provided for the diagnosis and treatment of inflammation and autoimmune disorders, such as psoriasis. Compositions and methods for modulating IL-23 or IL-22 signaling are provided.
摘要翻译：提供了用于诊断和治疗炎症和自身免疫性疾病如牛皮癣的组合物和方法。提供了调节IL-23或IL-22信号传导的组合物和方法。

67. 发明授权

US09550973B2 Bacterial host strain 有权
标题翻译：细菌宿主菌株
公开(公告)号：US09550973B2
公开(公告)日：2017-01-24
申请号：US15083446
申请日：2016-03-29
申请人： UCB PHARMA, S.A.
发明人： Mark Ellis , David Paul Humphreys
IPC分类号： C12P21/02 , C12N1/20 , C12R1/19 , C07K16/24 , C12N9/52 , C12N15/70
CPC分类号： C12N1/20 , C07K16/241 , C07K16/244 , C07K2317/14 , C07K2317/20 , C07K2317/55 , C12N9/52 , C12N15/70 , C12P21/02 , C12R1/19 , Y02P20/52
摘要： A recombinant gram-negative bacterial cell comprising one or more of the following mutated protease genes: a) a mutated Tsp gene, wherein the mutated Tsp gene encodes a Tsp protein having reduced protease activity or is a knockout mutated Tsp gene; b) a mutated ptr gene, wherein the mutated ptr gene encodes a Protease III protein having reduced protease activity or is a knockout mutated ptr gene; and c) a mutated DegP gene encoding a DegP protein having chaperone activity and reduced protease activity; wherein the cell is isogenic to a wild-type bacterial cell except for the mutated Tsp gene and/or mutated ptr gene and/or mutated DegP gene and optionally a polynucleotide sequence encoding a protein of interest.
摘要翻译：包含一个或多个以下突变蛋白酶基因的重组革兰氏阴性细菌细胞：a）突变的Tsp基因，其中突变的Tsp基因编码具有降低的蛋白酶活性的Tsp蛋白或是敲除突变的Tsp基因; b）突变的ptr基因，其中突变的ptr基因编码具有降低的蛋白酶活性的蛋白酶III蛋白质或是敲除突变的ptr基因; 和c）编码具有伴侣活性和降低的蛋白酶活性的DegP蛋白的突变DegP基因; 其中所述细胞与野生型细菌细胞是同基因的，除了突变的Tsp基因和/或突变的ptr基因和/或突变的DegP基因和任选的编码目的蛋白质的多核苷酸序列。

68. 发明申请

US20170015747A1 CD86 ANTAGONIST MULTI-TARGET BINDING PROTEINS 审中-公开
标题翻译： CD86拮抗剂多目标结合蛋白
公开(公告)号：US20170015747A1
公开(公告)日：2017-01-19
申请号：US15281441
申请日：2016-09-30
申请人： APTEVO RESEARCH AND DEVELOPMENT LLC
发明人： Peter Armstrong Thompson , Peter Robert Baum , Philip Tan , John W. Blankenship , Sateesh Kumar Natarajan
IPC分类号： C07K16/28 , C07K16/24
CPC分类号： C07K16/2827 , A61K39/00 , A61K39/39558 , A61K2039/505 , C07K14/5428 , C07K14/70521 , C07K16/244 , C07K16/248 , C07K16/2818 , C07K16/2833 , C07K16/2875 , C07K16/2878 , C07K2317/24 , C07K2317/31 , C07K2317/53 , C07K2317/55 , C07K2317/622 , C07K2317/75 , C07K2317/76 , C07K2317/92 , C07K2319/70
摘要： This disclosure provides a multi-specific fusion protein composed of a CD86 antagonist binding domain and another binding domain that is an IL-10 agonist, an HLA-G agonist, an HGF agonist, an IL-35 agonist, a PD-1 agonist, a BTLA agonist, a LIGHT antagonist, a GITRL antagonist or a CD40 antagonist. The multi-specific fusion protein may also include an intervening domain that separates the other domains. This disclosure also provides polynucleotides encoding the multi-specific fusion proteins, compositions of the fusion proteins, and methods of using the multi-specific fusion proteins and compositions.
摘要翻译：本公开提供了由CD86拮抗剂结合结构域和作为IL-10激动剂，HLA-G激动剂，HGF激动剂，IL-35激动剂，PD-1激动剂的另一结合结构域组成的多特异性融合蛋白， BTLA激动剂，LIGHT拮抗剂，GITRL拮抗剂或CD40拮抗剂。多特异性融合蛋白还可以包括分隔其他结构域的中间结构域。本公开还提供了编码多特异融合蛋白的多核苷酸，融合蛋白的组合物，以及使用多特异性融合蛋白和组合物的方法。

69. 发明申请

US20170014355A1 CANNABINOID RECEPTOR TREATMENTS 有权
标题翻译： CANNABINOID受体治疗
公开(公告)号：US20170014355A1
公开(公告)日：2017-01-19
申请号：US14239413
申请日：2012-08-17
申请人： Toby K. EISENSTEIN , Rebecca R. HARTZELL , Martin W. ALDER , Joseph J. MEISSIER
发明人： Toby K. EISENSTEIN , Rebecca R. HARTZELL , Martin W. ALDER , Joseph J. MEISSIER
IPC分类号： A61K31/09 , A61K31/352 , C07K16/24 , A61K31/454 , A61K31/404 , A61K39/395 , A61K45/06 , A61K31/415
CPC分类号： A61K31/09 , A61K31/095 , A61K31/35 , A61K31/352 , A61K31/404 , A61K31/415 , A61K31/454 , A61K39/3955 , A61K45/06 , C07K16/244
摘要： The present invention includes methods and compositions for treating a transplant recipient by administration of a CB2 receptor agonist either alone or in combination with one or more active pharmaceutical ingredients to block the rejection of foreign tissue and prolong grafted organs, tissues and cells.
摘要翻译：本发明包括通过单独或与一种或多种活性药物成分组合施用CB2受体激动剂来治疗移植受体的方法和组合物，以阻断外来组织的排斥并延长移植的器官，组织和细胞。

70. 发明申请

US20170002073A1 COMPOSITIONS AND METHODS FOR MODULATING AN IMMUNE RESPONSE 审中-公开
标题翻译：用于调节免疫应答的组合物和方法
公开(公告)号：US20170002073A1
公开(公告)日：2017-01-05
申请号：US15039524
申请日：2014-11-25
申请人： THE BRIGHAM AND WOMEN'S HOSPITAL, INC.
发明人： Richard S. Blumberg , Kristi Baker , Timo Rath
IPC分类号： C07K16/28 , C12N15/113 , G01N33/564 , G01N33/68 , G01N33/574 , C07K16/00 , A61K39/00
CPC分类号： C07K16/283 , A61K39/0011 , A61K2039/505 , A61K2039/507 , C07K16/00 , C07K16/244 , C07K2317/21 , C07K2317/31 , C07K2317/52 , C07K2317/72 , C07K2317/76 , C12N15/1138 , C12N2310/14 , G01N33/564 , G01N33/574 , G01N33/6854 , G01N33/6863 , G01N33/6866 , G01N33/6869 , G01N2333/525 , G01N2333/5434 , G01N2333/57 , G01N2800/52
摘要： Described herein are compositions for increasing IL-12 production comprising IgG or a fragment thereof or a variant thereof and uses of said compositions for treating cancer and infectious diseases. Also described herein are compositions for decreasing IL-12 production comprising an agent that inhibits signaling mediated by interaction between FcRn and IgG and uses of said compositions for treating autoimmune diseases. Further described herein are methods for assessing efficacy of treatment by monitoring levels of various cytokines in the subject.
摘要翻译：本文描述了用于增加包含IgG或其片段或其变体的IL-12产生的组合物和所述组合物用于治疗癌症和感染性疾病的用途。本文还描述了用于降低IL-12产生的组合物，其包含抑制由FcRn和IgG之间的相互作用介导的信号传导的药剂和所述组合物用于治疗自身免疫性疾病的用途。本文进一步描述的是通过监测受试者中各种细胞因子的水平来评估治疗功效的方法。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式